‘Top Medical Innovators’ Honor Recognizes GNS for Work in Multiple Myeloma
CAMBRIDGE, Mass. – Dec. 9, 2014 – GNS Healthcare (GNS), a leading provider of analytics solutions for driving personalized interventions that improve population health, today announced that its CEO and co-founder, Colin Hill, has been honored by Scientific American Worldview as a Top Medical Innovator.
The honor, given in partnership with The Center for Medicine in the Public Interest (CMPI), recognizes Hill and the patented GNS inference engine and simulation platform, REFS™, for extraordinary contributions in hematology, specifically for becoming the first company to successfully turn big data into predictive models for drug development and treatment selection in multiple myeloma.
“The technology this honor recognizes simply did not exist until recently, says Colin Hill, CEO and co-founder of GNS. “Today we can discover causal drivers and underlying molecular processes from immense genomic and clinical datasets. We are reliably and consistently achieving results that accelerate many of the traditional steps in the drug discovery and development process and enable better matching of promising current treatments to patients for improved outcomes.”
“Innovators like Colin Hill often go unrecognized, yet their contributions are changing medical science and, in the case of GNS, radically accelerating drug discoveries and treatments,” says Jeremy Abbate, publishing director for Scientific American Worldview. “It is essential for the scientific community to honor imaginative and meaningful advances of this magnitude.”
Scientific American Worldview and CMPI honored Hill at a Dec. 8 reception held in conjunction with the American Society of Hematology Annual Meeting in San Francisco.
About GNS Healthcare
GNS Healthcare provides analytic solutions that predict the impact of individual interventions to improve population health and reduce costs. Based on the MAX™ Care Management Architecture and patented REFS™ inference engine, GNS helps health plans and providers plan, implement and measure interventions that benefit individuals and drive population-level ROI. These cloud-based solutions are being deployed to improve outcomes associated with medication non-adherence, metabolic syndrome, diabetes, pre-term birth, and specialty care medications. GNS solutions focus on reducing adverse events, slowing disease progression, and improving therapeutic effectiveness through precision selection that reduces wasteful spending and maximizes impact.
GNS Healthcare, Driving Intelligent Interventions
Media Contact
Gina Veazey
703-254-6276
gveazey@gnshealthcare.com